<h1 itemprop="aspect"> <strong>Surfaxin Side Effects</strong></h1><div class="thumbnail-div"> <img width="84" height="84" src="http://www.bad-drug.net/wp-content/uploads/2012/08/surfaxin-84x84.jpg?1df917" class="attachment-84x84 wp-post-image" alt="Surfaxin" title="Surfaxin" pagespeed_url_hash="4188810372" onload="pagespeed.CriticalImages.checkImageForCriticality(this);"/></div><h1>Serious Side Effects of Surfaxin</h1><ul><li>Surfaxin is not indicated for acute respiratory distress syndrome (ARDS). When administered to adults via segmental bronchoscopic lavage to treat ARDS, there was an increased incidence of death, multi-organ failure, sepsis, anoxic encephalopathy, renal failure, hypoxia, pneumothorax, hypotension, and pulmonary embolism.</li><li>Treatment should be interrupted and the infant should be stabilized if it experiences<ul><li><strong>Bradycardia</strong> - an unnatural heart rhythm</li><li>O<strong>xygen desaturation</strong> - insufficient amounts of oxygen in the blood</li><li>Reflux of Surfaxin into the endotracheal tube (ETT)</li><li>Airway or ETT obstruction</li></ul></li></ul><h2>Common Side Effects of Surfaxin</h2><ul><li>Endotracheal tube reflux</li><li>Endotracheal tube obstruction</li><li>An unhealthy pale appearance, or pallor</li><li>Need for dose interruption</li></ul></div><div class="v" id="tab2" ><h2 itemprop="aspect"> <strong> Warnings & Recalls for Surfaxin </strong></h2><h2>General Surfaxin Warnings</h2><ul><li>Infants given Surfaxin treatments should receive frequent assessments to ensure that oxygen and ventilator support is modified for changed in respiratory changes.</li></ul></div><div class="v" id="tab3" ><h2 itemprop="aspect"> <strong> Surfaxin Treatment and Use </strong></h2><div class="thumbnail-div"> <img width="84" height="84" src="http://www.bad-drug.net/wp-content/uploads/2012/08/surfaxin-84x84.jpg?1df917" class="attachment-84x84 wp-post-image" alt="Surfaxin" title="Surfaxin" pagespeed_url_hash="4188810372" onload="pagespeed.CriticalImages.checkImageForCriticality(this);"/></div><p><strong>Surfaxin | </strong>lucinactant is a preventative surfactant treatment for respiratory distress syndrome (RDS) in premature infants who have a higher chance of developing this life-threatening condition. It is the only alternative to animal-derived surfactant.</p><h2>How does Surfaxin work?</h2><p>Respiratory distress syndrome is caused by a shortage of pulmonary surfactant, a liquid which is vital for healthy lung function. Surfaxin is a synthetic version of this liquid, and helps premature infants breathe by providing additional surfactant and lowering surface tension during breathing.</p><h2>Surfaxin Dosage Information</h2><p>Surfaxin is administered intratracheally by a clinicians trained in intubation, ventilator use, and care of premature infants.</p><p>The usual dose of Surfaxin is 5.8 mL per kg in birth weight. Within the first 48 hours of life, up to four doses six hours apart.</p></div><div class="v" id="tab4" ><h2 itemprop="aspect"> Other Names for Surfaxin</h2> <strong>Brand name</strong>:<br/><ul><br/><li>Surfaxin</li><br/></ul><br/> <strong>Generic name</strong>:<br/><ul><br/><li>Lucinactant</li><br/></ul></div><div class="v" id="tab5" ><h2 itemprop="aspect"> <strong> Lawsuits & Legal Information for Surfaxin </strong></h2>